Intensive antiplatelet — Competitive Intelligence Brief

Intensive antiplatelet (Intensive antiplatelet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combination. Area: Cardiovascular.

phase 3 Antiplatelet agent combination Cardiovascular Small molecule

Target snapshot

Intensive antiplatelet (Intensive antiplatelet) — Beijing Tiantan Hospital. Intensive antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intensive antiplatelet TARGET	Intensive antiplatelet	Beijing Tiantan Hospital	phase 3	Antiplatelet agent combination
OAC + clopicogrel	OAC + clopicogrel	St. Antonius Hospital	marketed	Anticoagulant + antiplatelet agent combination	Coagulation cascade (OAC) and P2Y12 receptor (clopidogrel)
Clopidogrel, cilostazol	Clopidogrel, cilostazol	Kyunghee University Medical Center	marketed	Antiplatelet agent combination	P2Y12 receptor (clopidogrel); phosphodiesterase-3 (cilostazol)
aspirin + clopidogrel + celecoxib	aspirin + clopidogrel + celecoxib	Seoul National University Hospital	marketed	Antiplatelet agent combination with NSAID	COX-1, P2Y12 receptor, COX-2
Dual antithrombotc therapy-1	Dual antithrombotc therapy-1	The First Affiliated Hospital with Nanjing Medical University	marketed	Antiplatelet agent combination
Rosuvastatin plus clopidogrel	Rosuvastatin plus clopidogrel	Federal University of São Paulo	marketed	Statin plus antiplatelet agent combination	HMG-CoA reductase; P2Y12 receptor
Ticagrelor plus aspirin	Ticagrelor plus aspirin	Fujian Medical University	marketed	Dual antiplatelet agent combination	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combination class)

1. Beijing Tiantan Hospital · 1 drug in this class
2. Biosensors Europe SA · 1 drug in this class
3. Inova Health Care Services · 1 drug in this class
4. Kyunghee University Medical Center · 1 drug in this class
5. Seoul National University Hospital · 1 drug in this class
6. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
7. University Hospital, Bordeaux · 1 drug in this class